Literature DB >> 7706467

Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

L Diller1, E Sexsmith, A Gottlieb, F P Li, D Malkin.   

Abstract

We investigated the possibility that a proportion of children with sporadic rhabdomyosarcoma (RMS) carry constitutional mutations of the p53 tumor suppressor gene. 33 patients with sporadic RMS at two large outpatient pediatric oncology clinics submitted blood samples. Genomic DNA was extracted from peripheral blood leukocytes and PCR was used to amplify exons 2-11 of the p53 gene. Amplified genomic DNA was screened for the presence of germline p53 mutations using single-strand conformation polymorphism (SSCP) analysis. The DNA sequence of those samples that showed aberrant migration of bands on SSCP analysis was determined to identify the precise nature of the gene mutations. Patient records were reviewed to assess clinical correlates of the mutant p53 carrier state. Heterozygous constitutional mutations were detected in 3/33 patient samples screened. Two of these missense mutations are located in exon 7 and one in exon 8 of the p53 gene. The presence of mutations was not correlated with tumor histology, stage, or site. However, an association between young age at diagnosis and presence of a constitutional p53 mutation was noted: 3/13 children under the age of 3 yr at diagnosis carried mutations, whereas none of 20 children over 3 yr of age at diagnosis harbored a detectable constitutional mutation. These results in children with RMS corroborates previous findings in other clinical settings suggesting that the mutant p53 carrier state may predispose individuals to malignancy at an early age. Although this study did not assess whether the mutations were preexisting or new germline alterations, assessment of close relatives of RMS patients for cancer risk and predictive genetic testing may be indicated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706467      PMCID: PMC295658          DOI: 10.1172/JCI117834

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Polymorphism at codon 213 within the p53 gene.

Authors:  D Carbone; I Chiba; T Mitsudomi
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

2.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

Review 3.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

4.  High frequency of germline p53 mutations in childhood adrenocortical cancer.

Authors:  J Wagner; C Portwine; K Rabin; J M Leclerc; S A Narod; D Malkin
Journal:  J Natl Cancer Inst       Date:  1994-11-16       Impact factor: 13.506

5.  Follow-up study of twenty-four families with Li-Fraumeni syndrome.

Authors:  J E Garber; A M Goldstein; A F Kantor; M G Dreyfus; J F Fraumeni; F P Li
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

6.  Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.

Authors:  J F McIntyre; B Smith-Sorensen; S H Friend; J Kassell; A L Borresen; Y X Yan; C Russo; J Sato; N Barbier; J Miser
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

7.  Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.

Authors:  S Mashiyama; Y Murakami; T Yoshimoto; T Sekiya; K Hayashi
Journal:  Oncogene       Date:  1991-08       Impact factor: 9.867

8.  Mutations of the p53 gene do not occur in testis cancer.

Authors:  H Q Peng; D Hogg; D Malkin; D Bailey; B L Gallie; M Bulbul; M Jewett; J Buchanan; P E Goss
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

9.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.

Authors:  J M Birch; A L Hartley; K J Tricker; J Prosser; A Condie; A M Kelsey; M Harris; P H Jones; A Binchy; D Crowther
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

10.  Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.

Authors:  A Zauberman; Y Barak; N Ragimov; N Levy; M Oren
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

View more
  47 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

2.  Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.

Authors:  Doris Phelps; Kathryn Bondra; Star Seum; Christopher Chronowski; Justin Leasure; Raushan T Kurmasheva; Steven Middleton; Dian Wang; Xiaokui Mo; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2015-04-01       Impact factor: 3.167

3.  Intraperitoneal dedifferentiated liposarcoma: a case report.

Authors:  Ali Karaman; Mehmet-Esref Kabalar; Onder Ozcan; Timur Koca; Dogan-Nasir Binici
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

Review 4.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

5.  Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Authors:  Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova
Journal:  Pathol Oncol Res       Date:  2014-08-23       Impact factor: 3.201

Review 6.  The role of p53 in human cancer.

Authors:  D Malkin
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

7.  RAS and ROS in rhabdomyosarcoma.

Authors:  Minsi Zhang; Corinne M Linardic; David G Kirsch
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

8.  Germline TP53 variants and susceptibility to osteosarcoma.

Authors:  Lisa Mirabello; Meredith Yeager; Phuong L Mai; Julie M Gastier-Foster; Richard Gorlick; Chand Khanna; Ana Patiño-Garcia; Luis Sierrasesúmaga; Fernando Lecanda; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Donald A Barkauskas; Xijun Zhang; Aurelie Vogt; Kristine Jones; Joseph F Boland; Stephen J Chanock; Sharon A Savage
Journal:  J Natl Cancer Inst       Date:  2015-04-20       Impact factor: 13.506

9.  Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype.

Authors:  S Ognjanovic; S E Carozza; E J Chow; E E Fox; S Horel; C C McLaughlin; B A Mueller; S Puumala; P Reynolds; J Von Behren; L Spector
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

10.  Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  A S Pappo; G T Armstrong; W Liu; D K Srivastava; A McDonald; W M Leisenring; S Hammond; M Stovall; J P Neglia; L L Robison
Journal:  Pediatr Blood Cancer       Date:  2012-08-08       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.